Trial Profile
A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms KEYNOTE 483
- 12 Jan 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
- 07 Nov 2023 Results assessing whether the addition of pembrolizumab to platinum pemetrexed would improve overall survival in patients with pleural mesothelioma, published in the Lancet
- 03 Aug 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.